The N-Terminus of the HIV-1 P6 Gag Protein Regulates Susceptibility to Degradation by IDE

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2018 Dec 15

PMID 30545091

Citations 4

Authors

Adrian Schmalen

Julia Karius-Fischer

Pia Rauch

Christian Setz

Klaus Korn

Petra Henklein

Torgils Fossen

Ulrich Schubert

Affiliations

Soon will be listed here.

Abstract

As part of the Pr55 polyprotein, p6 fulfills an essential role in the late steps of the replication cycle. However, almost nothing is known about the functions of the mature HIV-1 p6 protein. Recently, we showed that p6 is a bona fide substrate of the insulin-degrading enzyme (IDE), a ubiquitously expressed zinc metalloprotease. This phenomenon appears to be specific for HIV-1, since p6 homologs of HIV-2, SIV and EIAV were IDE-insensitive. Furthermore, abrogation of the IDE-mediated degradation of p6 reduces the replication capacity of HIV-1 in an Env-dependent manner. However, it remained unclear to which extent the IDE mediated degradation is phylogenetically conserved among HIV-1. Here, we describe two HIV-1 isolates with IDE resistant p6 proteins. Sequence comparison allowed deducing one single amino acid regulating IDE sensitivity of p6. Exchanging the N-terminal leucine residue of p6 derived from the IDE sensitive isolate HIV-1 with proline enhances its stability, while replacing Pro-1 of p6 from the IDE insensitive isolate SG3 with leucine restores susceptibility towards IDE. Phylogenetic analyses of this natural polymorphism revealed that the N-terminal leucine is characteristic for p6 derived from HIV-1 group M except for subtype A, which predominantly expresses p6 with an N-terminal proline. Consequently, p6 peptides derived from subtype A are not degraded by IDE. Thus, IDE mediated degradation of p6 is specific for HIV-1 group M isolates and not occasionally distributed among HIV-1.

Citing Articles

Altered Surface Expression of Insulin-Degrading Enzyme on Monocytes and Lymphocytes from COVID-19 Patients Both at Diagnosis and after Hospital Discharge.

Gonzalez-Casimiro C, Arribas-Rodriguez E, Fiz-Lopez A, Casas J, Gutierrez S, Telleria P Int J Mol Sci. 2022; 23(19).

PMID: 36232381 PMC: 9570012. DOI: 10.3390/ijms231911070.

Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.

Gonzalez-Casimiro C, Merino B, Casanueva-Alvarez E, Postigo-Casado T, Camara-Torres P, Fernandez-Diaz C Biomedicines. 2021; 9(1).

PMID: 33477364 PMC: 7830943. DOI: 10.3390/biomedicines9010086.

Regulators of Viral Frameshifting: More Than RNA Influences Translation Events.

Penn W, Harrington H, Schlebach J, Mukhopadhyay S Annu Rev Virol. 2020; 7(1):219-238.

PMID: 32600156 PMC: 8310556. DOI: 10.1146/annurev-virology-012120-101548.

Genetic Analysis of the Full-Length Gene from the Earliest Korean Subclade B of HIV-1: An Outbreak among Korean Hemophiliacs.

Cho Y, Kim J, Foley B Viruses. 2019; 11(6).

PMID: 31212650 PMC: 6631484. DOI: 10.3390/v11060545.

References

Malet I, Roquebert B, Dalban C, Wirden M, Amellal B, Agher R . Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect. 2006; 54(4):367-74. DOI: 10.1016/j.jinf.2006.06.012. View

Van Heuverswyn F, Li Y, Bailes E, Neel C, Lafay B, Keele B . Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon. Virology. 2007; 368(1):155-71. DOI: 10.1016/j.virol.2007.06.018. View

Authier F, Bergeron J, Ou W, Rachubinski R, Posner B, Walton P . Degradation of the cleaved leader peptide of thiolase by a peroxisomal proteinase. Proc Natl Acad Sci U S A. 1995; 92(9):3859-63. PMC: 42061. DOI: 10.1073/pnas.92.9.3859. View

Kurochkin I . Amyloidogenic determinant as a substrate recognition motif of insulin-degrading enzyme. FEBS Lett. 1998; 427(2):153-6. DOI: 10.1016/s0014-5793(98)00422-0. View

Liu K, Warnow T, Holder M, Nelesen S, Yu J, Stamatakis A . SATe-II: very fast and accurate simultaneous estimation of multiple sequence alignments and phylogenetic trees. Syst Biol. 2011; 61(1):90-106. DOI: 10.1093/sysbio/syr095. View

Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E . Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000; 6(2):143-50. DOI: 10.1038/72237. View

Robertson D, Hahn B, Sharp P . Recombination in AIDS viruses. J Mol Evol. 1995; 40(3):249-59. DOI: 10.1007/BF00163230. View

MIRSKY I, PERISUTTI G . Effect of insulinase-inhibitor on hypoglycemic action of insulin. Science. 1955; 122(3169):559-60. View

Gottlinger H, Dorfman T, Sodroski J, Haseltine W . Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A. 1991; 88(8):3195-9. PMC: 51412. DOI: 10.1073/pnas.88.8.3195. View

10.

Halle M, Tribout-Jover P, Lanteigne A, Boulais J, St-Jean J, Jodoin R . Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies. J Immunol Methods. 2015; 424:64-79. DOI: 10.1016/j.jim.2015.05.002. View

11.

Hemelaar J, Gouws E, Ghys P, Osmanov S . Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006; 20(16):W13-23. DOI: 10.1097/01.aids.0000247564.73009.bc. View

12.

Huet T, Cheynier R, Meyerhans A, Roelants G, Wain-Hobson S . Genetic organization of a chimpanzee lentivirus related to HIV-1. Nature. 1990; 345(6273):356-9. DOI: 10.1038/345356a0. View

13.

Shen Y, Joachimiak A, Rosner M, Tang W . Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature. 2006; 443(7113):870-4. PMC: 3366509. DOI: 10.1038/nature05143. View

14.

Sacktor N, Nakasujja N, Skolasky R, Rezapour M, Robertson K, Musisi S . HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis. 2009; 49(5):780-6. PMC: 2941149. DOI: 10.1086/605284. View

15.

Verheyen J, Litau E, Sing T, Daumer M, Balduin M, Oette M . Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther. 2007; 11(7):879-87. View

16.

Tamiya S, Mardy S, Kavlick M, Yoshimura K, Mistuya H . Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol. 2004; 78(21):12030-40. PMC: 523239. DOI: 10.1128/JVI.78.21.12030-12040.2004. View

17.

Darke P, NUTT R, Brady S, Garsky V, Ciccarone T, Leu C . HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem Biophys Res Commun. 1988; 156(1):297-303. DOI: 10.1016/s0006-291x(88)80839-8. View

18.

Huang M, Orenstein J, Martin M, Freed E . p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol. 1995; 69(11):6810-8. PMC: 189593. DOI: 10.1128/JVI.69.11.6810-6818.1995. View

19.

Paxton W, Connor R, Landau N . Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol. 1993; 67(12):7229-37. PMC: 238185. DOI: 10.1128/JVI.67.12.7229-7237.1993. View

20.

Peeters M, Gueye A, Mboup S, Bibollet-Ruche F, Ekaza E, Mulanga C . Geographical distribution of HIV-1 group O viruses in Africa. AIDS. 1997; 11(4):493-8. DOI: 10.1097/00002030-199704000-00013. View